Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways

Respirology

Volumn 21, Issue 6, 2016, Pages 1075-1080

  Chen, Bi ^a   Cai, Hou Rong ^b   Xue, Shan ^a   You, Wen Jie ^a   Liu, Bin ^a   Jiang, Han Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

bile acids; farnesoid X receptor; gastroesophageal reflux; idiopathic pulmonary fibrosis; myofibroblasts

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BILE ACID; CHENODEOXYCHOLIC ACID; COLLAGEN TYPE 1; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FIBRONECTIN; LAMININ; LITHOCHOLIC ACID; REACTIVE OXYGEN METABOLITE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

ADULT; ANIMAL CELL; ARTICLE; BRONCHIAL EPITHELIAL CELL; CELL ACTIVATION; CELL DAMAGE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROBLAST; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84978835125     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12815     Document Type: Article

References (37)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
2. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 13180–5.
3. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 2005; 166: 1321–32.
4. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest. 2009; 119: 213–24.
5. Xi Y, Tan K, Brumwell AN, Chen SC, Kim YH, Kim TJ, Wei Y, Chapman HA. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am. J. Respir. Cell Mol. Biol. 2014; 50: 51–60.
6. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132: 1311–21.
7. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TJ. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am. J. Med. 2010; 123: 304–11.
8. Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2013; 42: 1322–31.
9. Tobin RW, Pope CN, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158: 1804–8.
10. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129: 794–800.
11. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TJ, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 1390–4.
12. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 2013; 1: 369–76.
13. Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. Efficacy of esomeprazole for treatment of poorly controlled asthma. N. Engl. J. Med. 2009; 360: 1487–99.
14. Kilduff CE, Counter MJ, Thomas GA, Harrison NK, Hope-Gill BD. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough 2014; 10: 4.
15. Downing TE, Sporn TA, Bollinger RR, Davis RD, Parker W, Lin SS. Pulmonary histopathology in an experimental model of chronic aspiration is independent of acidity. Exp. Biol. Med. (Maywood) 2008; 233: 1202–12.
16. Pauwels A, Decraene A, Blondeau K, Mertens V, Farre R, Proesmans M, Van Bleyenbergh P, Sifrim D, Dupont LJ. Bile acids in sputum and increased airway inflammation in patients with cystic fibrosis. Chest 2012; 141: 1568–74.
17. Starosta V, Kitz R, Hartl D, Marcos V, Reinhardt D, Griese M. Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux disease. Chest 2007; 132: 1557–64.
18. Hallal C, Chaves VS, Borges GC, Werlang IC, Fontella FU, Matte U, Goldani MZ, Carvalho PR, Trotta EA, Piva JP et al. Acid and Weakly Acidic Gastroesophageal Reflux and Pepsin Isoforms (A and C) in Tracheal Secretions of Critically Ill Children. Chest 2015; 148: 333–9.
19. Zecca E, De Luca D, Baroni S, Vento G, Tiberi E, Romagnoli C. Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study. Pediatrics 2008; 121: e146–9.
20. Kaneko T, Sato T, Katsuya H, Miyauchi Y. Surfactant therapy for pulmonary edema due to intratracheally injected bile acid. Crit. Care Med. 1990; 18: 77–83.
21. Zhangxue H, Min G, Jinning Z, Yuan S, Li W, Huapei S, Rui L, Chunyu Z. Glycochenodeoxycholate induces rat alveolar epithelial type II cell death and inhibits surfactant secretion in vitro. Free Radic. Biol. Med. 2012; 53: 122–8.
22. Su KC, Wu YC, Chen CS, Hung MH, Hsiao YH, Tseng CM, Chang SC, Lee YC, Perng DW. Bile acids increase alveolar epithelial permeability via mitogen-activated protein kinase, cytosolic phospholipase A2, cyclooxygenase-2, prostaglandin E2 and junctional proteins. Respirology 2013; 18: 848–56.
23. Perng DW, Chang KT, Su KC, Wu YC, Wu MT, Hsu WH, Tsai CM, Lee YC. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation. Chest 2007; 132: 1548–56.
24. Hendrick SM, Mroz MS, Greene CM, Keely SJ, Harvey BJ. Bile acids stimulate chloride secretion through CFTR and calcium-activated Cl—channels in Calu-3 airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. 2014; 307: L407–18.
25. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 2006; 98: 192–9.
26. Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2013; 34: 638–46.
27. MacKenzie B, Korfei M, Henneke I, Sibinska Z, Tian X, Hezel S, Dilai S, Wasnick R, Schneider B, Wilhelm J et al. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir. Res. 2015; 16: 83.
28. Wu YC, Hsu PK, Su KC, Liu LY, Tsai CC, Tsai SH, Hsu WH, Lee YC, Perng DW. Bile acid aspiration in suspected ventilator-associated pneumonia. Chest 2009; 136: 118–24.
29. D'Ovidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, Hadjiliadis D, Chaparro C, Gutierrez C, Pierre A et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J. Thorac. Cardiovasc. Surg. 2005; 129: 1144–52.
30. Olman MA, White KE, Ware LB, Simmons WL, Benveniste EN, Zhu S, Pugin J, Matthay MA. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J. Immunol. 2004; 172: 2668–77.
31. Kage H, Borok Z. EMT and interstitial lung disease: a mysterious relationship. Curr. Opin. Pulm. Med. 2012; 18: 517–23.
32. Song P, Zhang Y, Klaassen CD. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol. Sci. 2011; 123: 359–67.
33. Fukase K, Ohtsuka H, Onogawa T, Oshio H, Ii T, Mutoh M, Katayose Y, Rikiyama T, Oikawa M, Motoi F et al. Bile acids repress E-cadherin through the induction of Snail and increase cancer invasiveness in human hepatobiliary carcinoma. Cancer Sci. 2008; 99: 1785–92.
34. Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008; 18: 1087–95.
35. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir. Res. 2002; 3: 13.
36. Zoz DF, Lawson WE, Blackwell TS. Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am. J. Med. Sci. 2011; 341: 435–8.
37. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir. Res. 2014; 15: 157.